TW201307339A - 化合物８-酮基-９-［３-（１Ｈ-苯并咪唑-２-基氧基）苯基］-４，５，６，７，８，９-六氫-２Ｈ-吡咯并［３，４-ｂ］喹啉-３-甲酸乙酯，鹽，結晶型，共晶體，調配物，製備方法，作為藥物之應用，醫藥組合物及特別作為奧諾拉（ＡＵＲＯＲＡ）激酶抑制劑之新用途 - Google Patents

化合物８-酮基-９-［３-（１Ｈ-苯并咪唑-２-基氧基）苯基］-４，５，６，７，８，９-六氫-２Ｈ-吡咯并［３，４-ｂ］喹啉-３-甲酸乙酯，鹽，結晶型，共晶體，調配物，製備方法，作為藥物之應用，醫藥組合物及特別作為奧諾拉（ＡＵＲＯＲＡ）激酶抑制劑之新用途 Download PDF

Info

Publication number
TW201307339A
TW201307339A TW100142135A TW100142135A TW201307339A TW 201307339 A TW201307339 A TW 201307339A TW 100142135 A TW100142135 A TW 100142135A TW 100142135 A TW100142135 A TW 100142135A TW 201307339 A TW201307339 A TW 201307339A
Authority
TW
Taiwan
Prior art keywords
compound
quinoline
phenyl
yloxy
pyrrolo
Prior art date
Application number
TW100142135A
Other languages
English (en)
Chinese (zh)
Inventor
Nathalie Arokiassamy
Pascal Billot
Jean-Christophe Carry
Patrick Clavieres
Francois Clerc
Veronique Crocq-Stuerga
Sylvette Lachaud
Philippe Lienard
Jerome Menegotto
Laurent Schio
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of TW201307339A publication Critical patent/TW201307339A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW100142135A 2010-11-17 2011-11-17 化合物８-酮基-９-［３-（１Ｈ-苯并咪唑-２-基氧基）苯基］-４，５，６，７，８，９-六氫-２Ｈ-吡咯并［３，４-ｂ］喹啉-３-甲酸乙酯，鹽，結晶型，共晶體，調配物，製備方法，作為藥物之應用，醫藥組合物及特別作為奧諾拉（ＡＵＲＯＲＡ）激酶抑制劑之新用途 TW201307339A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1059456A FR2967413A1 (fr) 2010-11-17 2010-11-17 Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.

Publications (1)

Publication Number Publication Date
TW201307339A true TW201307339A (zh) 2013-02-16

Family

ID=43759999

Family Applications (1)

Application Number Title Priority Date Filing Date
TW100142135A TW201307339A (zh) 2010-11-17 2011-11-17 化合物８-酮基-９-［３-（１Ｈ-苯并咪唑-２-基氧基）苯基］-４，５，６，７，８，９-六氫-２Ｈ-吡咯并［３，４-ｂ］喹啉-３-甲酸乙酯，鹽，結晶型，共晶體，調配物，製備方法，作為藥物之應用，醫藥組合物及特別作為奧諾拉（ＡＵＲＯＲＡ）激酶抑制劑之新用途

Country Status (5)

Country Link
AR (1) AR083901A1 (es)
FR (1) FR2967413A1 (es)
TW (1) TW201307339A (es)
UY (1) UY33738A (es)
WO (1) WO2012066486A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005018911D1 (de) * 2005-07-20 2010-03-04 Aventis Pharma Sa 1,4-Dihydropyridine-kondensierte Heterocyclen Verfahren zu deren Herstellung sowie Verwendung und Zusammensetzungen dergleichen
FR2945535B1 (fr) * 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
WO2012066486A1 (en) 2012-05-24
UY33738A (es) 2012-06-29
AR083901A1 (es) 2013-04-10
FR2967413A1 (fr) 2012-05-18

Similar Documents

Publication Publication Date Title
US20230303489A1 (en) Compounds, compositions and methods of use
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
CN107922425B (zh) 制备parp抑制剂、结晶形式的方法及其用途
KR101738866B1 (ko) 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도
KR20040111445A (ko) 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
EP3124486B1 (en) Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof
JP2012509912A (ja) 新規の化合物
KR20050013534A (ko) ｃ─Ｊｕｎ Ｎ─말단 키나아제 억제용 아자인돌
JPWO2019065791A1 (ja) 複素環化合物
KR20240040742A (ko) Kif18a 억제제로서의 화합물
US20230145793A1 (en) Substituted pyrimidine or pyridine amine derivative, composition thereof, and medical use thereof
CA2619706A1 (en) Novel high affinity quinoline-based kinase ligands
CN102066322A (zh) 具有npy y5受体拮抗作用的化合物
EP3845538B1 (en) Dihydroimidazopyrazinone compound, composition including same, and use thereof
TW201036977A (en) 6-(6-substituted triazolopyridazine-sulfanyl) 5-fluorobenzothiazole and 5-fluorobenzimidazole derivatives: preparation, and use as medicaments and as MET inhibitors
EP3848365A1 (en) Trk inhibitor as anti-cancer drug
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
EP2051985B1 (fr) Derives de pyrazolo[4,3-d]thiazole, leur preparation et leur application en therapeutique
CA3195127A1 (en) Rev-erb agonists
TW201307339A (zh) 化合物８-酮基-９-［３-（１Ｈ-苯并咪唑-２-基氧基）苯基］-４，５，６，７，８，９-六氫-２Ｈ-吡咯并［３，４-ｂ］喹啉-３-甲酸乙酯，鹽，結晶型，共晶體，調配物，製備方法，作為藥物之應用，醫藥組合物及特別作為奧諾拉（ＡＵＲＯＲＡ）激酶抑制劑之新用途
EP3481801B1 (en) Indoline derivatives and method for using and producing the same
EP3643718B1 (en) Heterocyclic compound and its use as positive allosteric modulator of the cholinergic muscarinic m1 receptor.
WO2019096112A1 (zh) 一种取代的苯并咪唑化合物及包含该化合物的组合物
BR112019025158A2 (pt) Derivados de ácido carboxílico como inibidores das proteínas quinase
WO2023138681A1 (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用